Earlier this week, the Volastra team came together for a fun-filled afternoon at Yankee Stadium. Taking a break from the office allowed us to relax and recharge, and to top it off, the Yankees won 9-1! ⚾️🌞 Here’s to continued teamwork, both on and off the field! Pictured: Cayley Gehnrich; Sarah Bettigole; Joseph Avallone; Derek Rookhuizen; Nazario Bosco; Song Chen; Charles Hugh-Jones; Scott Drutman MD PhD; Adriana Roopnariane; Maeve Morse-Seaverns; Linda Lee; Reka Letso; Cindy O.; Aaron Phillips; Jonathan Havel; Andrea Ozuna; Ryan Schulz; Christina Eng; Rachel Zolot Schwartz
Volastra Therapeutics
Biotechnology
New York, New York 4,281 followers
Clinical stage biotech developing a powerful new class of cancer therapies exploiting chromosomal instability.
Über uns
Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.
- Website
-
http://www.volastratx.com
External link for Volastra Therapeutics
- Industrie
- Biotechnology
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- New York, New York
- Typ
- In Privatbesitz
- Gegründet
- 2019
Standorte
-
Primäre
1361 Amsterdam Ave
520
New York, New York 10027, US
Employees at Volastra Therapeutics
Aktualisierungen
-
We are excited to announce an opening for the position of Associate Director / Director, Research & Development Program Management at Volastra Therapeutics, based in New York City. At Volastra, we are at the forefront of oncology biotechnology, leveraging chromosomal instability (CIN) to develop groundbreaking cancer therapeutics. As part of our dynamic and passionate team, the person in this role will play a pivotal role in integrating R&D functions to ensure smooth and consistent operations within our clinical-stage assets, with opportunities to engage across the entire R&D spectrum. For more details and to apply, visit https://lnkd.in/dDHCh2MG
-
#DYK that 60% to 80% of all cancers are chromosomally unstable? At Volastra, we are advancing two clinical-stage #KIF18A inhibitors, #sovilnesib and VLS-1488, designed to disrupt #cancer cell division and deliver enhanced efficacy across a broader patient population. Read as our CEO, Charles Hugh-Jones, discusses our story and how we are leveraging KIF18A inhibition to exploit #chromosomal_instability (CIN) in cancer cells in Life Science Leader’s latest ‘Companies to Watch’ feature by Ben Comer. Access the full article here: https://bit.ly/3VZLyLB
-
Join Volastra Therapeutics! Volastra Therapeutics is seeking a Research Associate II/Senior Research Associate in Tumor Immunology to join our NYC team. We are a clinical-stage oncology biotech focused on exploiting chromosomal instability (CIN) to combat cancer, backed by top venture firms and strategic partnerships. You'll collaborate with our scientific team to validate novel targets and advance key drug development programs, involving cell culture, gene expression manipulation, biochemical assays, and data analysis. Ready to make a difference? Apply here: https://lnkd.in/gVUEd-ru #Hiring #Oncology #ResearchAssociate #BiotechJobs #VolastraTherapeutics #CancerResearch #JoinOurTeam #NYCJobs
-
We are on the ground at #ASCO24 in Chicago! Connect with us to learn more about one of our two #clinicaltrials evaluating our internally discovered clinical-stage #KIF18A inhibitor, VLS-1488, in patients with advanced #cancers. View the abstract here: https://lnkd.in/e4nSvM8B American Society of Clinical Oncology (ASCO)
-
-
Heading to #ASCO24 next week? Join us as we provide an overview of our Phase I/II #clinicaltrial of VLS-1488, one of our clinical-stage #KIF18A inhibitors for patients with advanced #cancers. See more details below and view our full abstract here: https://lnkd.in/e4nSvM8B American Society of Clinical Oncology (ASCO)
-
Cheers to five years of dedication from our fantastic Volastra team in the fight against #cancer. As we look back on our team’s accomplishments and milestones, we’re proud of our growth and grateful for our collective commitment to advancing life-changing therapies for patients.
-
-
Volastra Therapeutics reposted this
We're expanding our team with two key roles: 1️⃣ Director/Senior Director, Biostatistics/Biometrics: Lead our Biostatistics function in the development of our clinical trial programs. Bring your extensive experience in oncology clinical trials and statistical analysis to drive successful outcomes. Learn more and apply here: https://lnkd.in/eH-5FrhE 2️⃣ Senior Scientist/Associate Director, Bioinformatics: Join our dynamic research team and contribute to the development of our preclinical and clinical stage assets. Apply your expertise in cancer biology, computational biology, and multi-modal data analysis to drive impactful discoveries. Learn more and apply here: https://lnkd.in/eQ6-Uwta At Volastra, you'll join a passionate team dedicated to advancing therapies for cancer patients. Visit our website to learn more about our mission and culture: www.volastratx.com. #VolastraTherapeutics #Biostatistics #Bioinformatics #OncologyResearch #ClinicalTrials #NowHiring #NYCJobs
-
Join us at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting next month! We look forward to sharing details from our ongoing Phase 1 trial investigating VLS-1488, one of our two clinical-stage #KIF18A inhibitors, for the treatment of advanced #cancers. #ASCO24
-
-
Our Head of Research & Development and Chief Medical Officer, Scott Drutman MD PhD, sat down with Madeleine Armstrong of ApexOnco to talk more about how we’re leveraging #KIF18A inhibition to disrupt #cancer cell division and create more effective therapeutics for cancer patients with our clinical-stage KIF18A inhibitors, VLS-1488 and sovilnesib. Check out the article: https://lnkd.in/ek9GDsYs